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Abstract
Alzheimer's disease (AD) is characterized by the presence of two histopathological hallmarks; the
senile plaques, or extracellular deposits mainly composed of amyloid-β peptide (Aβ), and the
neurofibrillary tangles, or intraneuronal inclusions composed of hyperphosphorylated tau protein.
Since Aβ aggregates are found in the pathological cases, several strategies are under way to develop
drugs that interact with Aβ to reduce its assembly. One of them is 3-amino-1-propane sulfonic acid
(Tramiprosate, 3-APS, Alzhemed™), that was developed as a sulfated glycosaminoglycan mimetic,
that could interact with Aβ peptide, preventing its aggregation.
However, little is known about the action of 3-APS on tau protein aggregation. In this work, we
have tested the action of 3-APS on cell viability, microtubule network, actin organization and tau
aggregation. Our results indicate that 3-APS favours tau aggregation, in tau transfected non-
neuronal cells, and in neuronal cells. We also found that 3-APS does not affect the binding of tau
to microtubules but may prevent the formation of tau-actin aggregates. We like to emphasize the
importance of testing on both types of pathology (amyloid and tau) the potential drugs to be used
for AD treatment.
Background
Alzheimer's disease is characterized by the presence of two
histopathological hallmarks; the senile plaques or extra-
cellular deposits mainly composed of amyloid-β peptide
(Aβ) and the neurofibrillary tangles or intraneuronal
inclusions composed of hyperphosphorylated tau protein
[1].
It has been proposed that some compounds like sulfated
glycosaminoglycans (sGAG) [2] could promote the aggre-
gation of Aβ and tau [3-5], and it has been even suggested
that in Alzheimer's disease sGAG may provide a common
link for Aβ and tau polymerization [3-8].
sGAG including heparan, keratan and chondroitin sul-
fates strongly favor Aβ polymerization in vitro [5,8,9]. Dif-
ferent sGAG also facilitate the assembly in vitro of tau
[3,4,10]. In addition Aβ [7,11] and tau aggregates [12]
associate to sGAG in vivo. On the other hand, the binding
of sGAG to Aβ has been found to decrease Aβ degradation
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through basic residues of the interacting proteins like Aβ
[14], supporting previous studies demonstrating the
importance of the sulfate moeities of sGAG for the forma-
tion of amyloid fibrils [15].
Since Aβ aggregates are found in Alzheimer's disease, sev-
eral strategies to develop drugs that interact with Aβ to
reduce its assembly are under way. Aβ peptide has been
taken as a suitable target to develop a therapy against
Alzheimer's disease as, at present, the prevalent theory of
Alzheimer's disease pathophysiology, the amyloid cas-
cade, hypothesizes that a reduction of Aβ may not only
improve amyloid pathology, but also tau pathology [16].
In this way, the action of some compounds have been
only tested on amyloid but not on tau pathology [17,18].
One of these compounds is 3-amino-1-propane sulfonic
acid (tramiprosate, 3-APS), also known as Alzhemed™
(the use of its trade name is only for identification pur-
poses) [19,20], that was developed as a sGAG mimetic
[21,22] that could interact with Aβ peptide, preventing its
aggregation.
Not only the contribution of the different forms of Aβ to
Alzheimer's disease pathology is uncertain and recent evi-
dence rather implicates soluble oligomers [23], but it is
generally accepted that blocking tau pathology could have
therapeutic benefit. In this work, we have tested the action
of 3-APS on tau aggregation. Our results indicate that 3-
APS favours tau aggregation, but with a different mecha-
nism to that found for other tau assembly inducers, like
heparin. We also found that 3-APS does not affect the
binding of tau to microtubules but may prevent the for-
mation of tau-actin aggregates.
Results
Effect of 3-APS on tau stably transfected HEK 293 cells
To study the direct effect of 3-APS on tau protein without
the interference of other neuronal proteins, non neuronal
cells, HEK 293, lacking tau were stably transfected with
human tau cDNA. The tau-expressing cells were identified
by immunofluorescence using an antibody raised against
tau. Figure 1 indicates that upon tau expression the trans-
fected cells show some microtubules bundles (see arrows
and inset in Figure 1A), and that the actin-stress fibers dis-
sappear. Moreover, some aggregates, where tau and actin
colocalize, were found at the cell membrane (see below).
These aggregates could be similar to those recently
reported in Drosophila cells [24]. In addition, the pres-
ence and quantitation of tau mRNA by RT-PCR, (Figure
1B) was determined, and the expression of tau protein
was also analyzed by Western blot (Figure 1C).
Quantitation of tau protein expressed in these cells, indi-
cated that tau was about 0.1 % of the total soluble cell
protein. Since the content of tubulin in these cells was
about 2 %, the ratio tau/tubulin was in line to that
described for neuronal cells [25].
Increasing amounts of 3-APS were added to untransfected
or transfected HEK 293 cells. Figure 2 indicates that upon
addition of increasing amounts of 3-APS, a slight increase
in tau staining was observed in tau transfected cells (see
Figures 2A, 2C). This was not due to an increase in the
amount of tau, as determined by Western blot (not
shown), but probably, to an increase in tau aggregation in
treated cells. Since tau aggregates are usually stained with
Thioflavin S (Th-S) [26], Th-S staining was performed on
the transfected cells after adding increasing amounts of 3-
APS. Figure 2B also shows that there was a clear increase
in Th-S staining dependent upon addition of increasing
amounts of 3-APS (see also Figure 2D).
To confirm the increase in tau aggregates in 3-APS-treated
cells, detergent insoluble aggregates were isolated and the
presence of tau protein in those aggregates was deter-
mined. Western blot analysis revealed the presence of tau
in the detergent insoluble fraction, and also showed that
the amount of tau in the aggregates increased with the
concentration of added 3-APS (Figure 3). When the same
experiments, shown in Figures 2 and 3, were done in the
presence of a sGAG, like heparin, instead of 3-APS, no dif-
ferences were found with respect to controls (absence of
heparin or 3-APS), when tau aggregation was tested. It can
be explained by the fact that 3-APS, but not heparin, can
enter into the cell.
3-APS facilitates tau assembly in vitro
To test if 3-APS directly facilitated the assembly of tau pro-
tein, purified recombinant tau protein was mixed with 3-
APS and, after incubation of the mixture (in the condi-
tions described in Materials and Methods), the aggregates
were visualized under electron microscopy. Figure 4A
shows the presence of short fibrillar polymers, upon addi-
tion of 3-APS; together with fewer but longer and larger
fibrillar polymers (inset of the figure). No polymers were
found in the absence of added tau. Some of the longer and
larger 3-APS induced polymers were similar to those
assembled in the presence of heparin (Figure 4B). When
tau protein was mixed with both 3-APS and heparin both
types of polymers were observed (Figure 4C). In addition,
we studied the formation of these aggregates by immun-
ofluorescence analysis [27], and we found that they could
be identified by Th-S staining (Figure 4D). The result
shown in Figure 4D suggests that the increased Th-S stain-
ing found upon 3-APS addition could be due to the pres-
ence of tau aggregates.Page 2 of 12
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affect to tau-actin interaction
The previous observation suggests that 3-APS binds to tau.
This binding could affect the interaction of tau with
microtubules and could result in a disorganization of
microtubule network. To test this possibility, immunoflu-
orescence analyses to visualize tubulin and tau were car-
ried out. No main differences were found upon addition
of 3-APS in microtubule network. Moreover, the in vitro
binding of tau to microtubules was studied in the absence
or presence of 3-APS. Our results indicated that in the
presence of 0.5 mM 3-APS there is a slight decrease of in
vitro tau binding to microtubules (Additional File 1).
Although the presence of 3-APS does not affect to the
organization of microtubule cytoskeleton, it seems to alter
some aspects related to tau-actin aggregates. In Figure 1, it
was shown that tau expression in HEK 293 cells resulted,
in keeping with previously reported data [28], in the loss
of actin stress fibers and in the presence of some aggre-
gates in lamellipodia-like structures that are stained with
phalloidin (aggregated actin) and tau antibodies
(recently, in PC12 cells, tau has been localized to lamel-
lipodia-like structures, where it associates with actin [29]).
These aggregates are shown in Figure 5A. Upon addition
of 3-APS these aggregates disappeared (Figure 5B) suggest-
ing that addition of 3-APS could result in the disasembly
of tau-actin aggregates.
3-APS is bound to tau when the C-terminal region of the 
protein is present
Since 3-APS is not affecting to the microtubule network
and to the binding of tau to microtubules, it is possible
that it does not bind directly to the microtubule binding
sites, found in tau molecule that are needed for tau-tau
interaction [4]. To look for the binding site of 3-APS that
results in tau aggregation we used different tau fragments
(see Figure 6A). Figure 6B shows that tau aggregates were
Levels of Tau in HEK 293 expressing Tau cell lineFigure 1
Levels of Tau in HEK 293 expressing Tau cell line. A) Immunofluorescence analysis of both HEK 293 and HEK 293 
expressing Tau cell lines using antibodies against β-tubulin, tau protein (Tau-5) and phalloidin to identifiy actin polymers. The 
results obtained for untransfected (left) and tau-transfected (right) cells are shown. In the presence of Tau, tubulin bundles 
were observed (see arrows). Inset shows a microtubule bundle inside HEK 293 tau expressing cells. B) RNA was isolated from 
previously mentioned cell lines as described in Materials and methods and a quantitative RT/PCR analysis using actin RNA, as 
internal control, was done. The size of the amplified DNA was determined by gel electrophoresis; Tau DNA, lanes 2 and 4 and 
actin DNA (lanes 3 and 5) are shown. In lane 1, are Hind III fragments of φ29 DNA used as electrophoretic markers. The quan-
titation of the ratio Tau/actin in arbitrary units is shown. C) Total protein extract from HEK 293 and HEK 293 expressing tau 
was obtained and Western blot analysis using an antibody against β-actin and an antibody (ab 7.51) against Tau, was done.Page 3 of 12
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APS. Very few polymers were found when tau 3R peptide
was tested and no polymers were observed for tau peptide
containing the amino-terminal half region of tau protein.
As can be seen also in the figure, larger polymers were
found for the tau variant in which the N-terminal region
was missing (tau 3RC) compared to the polymers found
when the whole tau was assembled. These data suggest
that 3-APS could bind to the C-terminal half region of tau
protein, explaining the lack of interference of 3-APS addi-
tion with tau binding to microtubules, since tau may
remain bound to microtubules and, also may bind to 3-
APS through to a more distal C-terminal region. It should
be indicated that tau binding to microtubules is mainly
through the first and second tubulin binding repeats
present in tau molecule [30].
It has been proposed that amyloid beta peptide fragment
Aβ1–28 binds to 3-APS [19]. The sequence of this peptide
being DAEFRHDSGYEVHHQKLVFFAEDVGSN K. The
bold motif has been suggested to be the binding site for 3-
APS [19]. Thus, we have looked for a similar motif in tau
molecule and it has been found a related motif NIHHK in
tau 3RC peptide. Thus, we have analyzed the polymeriza-
tion of a tau peptide containing the residues 317–335,
being NIHHK the residues 327 to 331 present in that pep-
tide. Figure 6B (inset) shows that the indicated tau peptide
(317–335) is able to assemble in the presence of 3-APS.
This experiment suggests a posible direct interaction
between tau peptide (residues 317–335) and 3-APS.
The presence of 3-APS-tau aggregates is not toxic for 
cultured non neuronal cells
To HEK 293 cells stably transfected with tau, increasing
amounts of 3-APS were added, and the cell viability was
measured. The data from Figure 7 show that, after four
days of 3-APS addition, the number of surviving cells was
similar at the different 3-APS concentrations tested in the
cell cultures and in controls without 3-APS. In every cell
culture, the presence of cells containing tau aggregates was
calculated based on Th-S staining, as previously shown in
Figure 2D for HEK 293 cells expressing tau protein.
Effect of 3-APS on Tau transfected cell lineFigure 2
Effect of 3-APS on Tau transfected cell line. HEK 293 expressing Tau cells were treated with 100 µM and 500 µM of 3-
APS and stained using an antibody against human Tau (ab T14) (A) or with 0.01 % thioflavin S (Th-S) (B). Quantitation of both 
T14 (C) and Thioflavin S (D) fluorescence observed by fluorescence microscopy is shown. The fluorescence intensity of each 
sample was obtained by background subtraction. A significant fluorescence intesity increase (P < 0.05 as compared with 
untreated cells) is shown for both T14 and Thioflavin S staining. The average of at least three separate determinations is indi-
cated. DAPI was used for nuclei staining.Page 4 of 12
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After looking at the effect of 3-APS in tau-expressing non
neuronal cells, we have tested the effect of 3-APS in
human SH-SY5Y neuroblastoma cells. These neuroblast-
oma cells express a very little amount of tau protein in
undifferentiated cells state. However, upon differentiation
(see methods), a high increase of tau protein was found in
those cells (Figure 8A). When undifferentiated neuroblas-
toma cells were treated with 3-APS, no differences in phal-
loidin staining (actin cytoskeleton) were found (Figure
8B). In fact, stress fibers were observed (probably due to
the low expression of tau protein). In addition, a very
weak Th-S staining was observed in the absence or pres-
ence of 3-APS. Upon differentiation of SH-SY5Y cells with
dibutyril cyclic AMP, stress fibers disappear (Figure 8C)
and very few actin-tau membrane complexes, compared
to those found in HEK 293 cells stably transfected with
tau, were observed. When these differentiated neuroblast-
oma cells were treated with 3-APS none of those actin-tau
complexes were found (Figure 8C). Moreover, in 3-APS
treated cells an increase in Th-S staining was observed
(Figure 8D). Also, an increase in detergent insoluble tau
aggregates was found upon treatment of the differentiated
SH-SY5Y cells with 3-APS (Figure 8E).
In addition, the effect of 3-APS on primary cultures of
mouse hipoccampal neurons was analyzed. Figure 8F
shows and increase in Th-S staining in 3-APS treated neu-
rons. The effect of 3-APS addition in neurons viability was
also studied, but not changes in cell viability was found in
the absence or presence of 3-APS (Figure 8G). Finally, no
differences in morphology of hipocacmpal neurons were
observed, upon 3-APS addition.
Discussion
The presence of amyloid deposits and tau aggregates are
the main characteristics of Alzheimer's disease, and could
be related to the neurodegenerative process. Usually, amy-
loid and tau pathologies are analyzed in an independent
way, and is not known if drugs preventing amyloid
Polymerization of Tau in the presence of 3-APSFigur  4
Polymerization of Tau in the presence of 3-APS. 
Fibrillar Tau polymers assembled in the presence of 3-APS 
were observed by Electron Microscopy. Mainly, short fibrillar 
and occasionally longer and wider filaments (inset) were 
found (A). These polymers are not identical to those found in 
the presence of heparin (B). An increase in both types was 
found in the presence of both heparin and 3-APS (C). Bars 
indicate 0.2 µm. 3-APS induced tau polymerization stained 
with Th-S and visualized by immunofluorescence (see meth-
ods) (D).
Tau aggregation in HEK 293 Tau expressing cells treated with 3-APSFigure 3
Tau aggregation in HEK 293 Tau expressing cells 
treated with 3-APS. Detergent insoluble aggregates of Tau 
were isolated from HEK 293 tau cells untreated (control) or 
treated with 3-APS. The detergent insoluble material (see 
methods) was analyzed by western blot using an antibody 
against Tau (ab 7.51). Reaction of the unfractionated cell 
extract with β-actin antibody, was used as loading control. 
The average of at least three separate determinations is indi-
cated. *, P < 0.05, **, P < 0.01 compared with control (Stu-
dent's t test).Page 5 of 12
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3-amino-1-propane sulfonic acid (3-APS), that maintains
beta amyloid peptide in non fibrillary form [19], whose
possible action on tau protein was unknown.
The aggregation of amyloid peptide, or tau protein, can be
induced by sGAG, like heparin. However, in the case of
amyloid peptide, low molecular weight heparin may
reduce the accumulation of beta amyloid aggregates in a
mouse model [17] and compounds, like 3-APS, that
mimic the binding of sGAG, can bind to soluble non-
fibrillar amyloid peptide, preventing amyloid aggregation
[21]. It has been also suggested that the sulfate moieties of
sGAG are sufficient to favour the formation of amyloid
fibrils [15], 3-APS has a sulfate moiety, but it appears that
this is not enough to induce amyloid aggregation.
In this work, we have found that 3-APS favours tau polym-
erization into fibrillar aggregates. The appearance of these
tau aggregates was not toxic in our cell model, and the
addition of 3-APS did not either result in toxicity to cul-
tured neurons. A possible explanation is that 3-APS binds
to tau protein through its C-terminal half region and, in
this way, it is not affecting to the microtubule binding
region present in tau protein, and therefore is not affecting
to the microtubule binding function of tau. 3-APS has
both a positively and a negatively charged regions. The
positively charged region of 3-APS could bind to the neg-
atively charged regions of tau protein, like those present at
the C-terminal region of tau, and in consequence, the neg-
ative influence of the C-terminal region of tau on its
selfassembly, would decrease upon 3-APS binding, allow-
ing tau poymerization [31]. On the other hand the nega-
tive charge region of 3-APS could bind to the positive
charges residues present in tau, in the C-terminal half of
the molecule, residues that are involved in the binding of
tau to actin. If it the case 3-APS and actin should compete
for the same tau-binding site. Also, it has been indicated
that tau binding to actin is through a region closed to the
C-terminal of tau molecule [29]. This region contains the
NIHHK motif, similar to the VHHQK motif that it has
been suggested to be required for the binding of 3-APS to
Aβ peptide [19].
Thus, in the presence of 3-APS, the binding of tau to actin
could be decreased if 3-APS overlaps its tau binding site
with that of actin. We can not exclude that 3-APS may also
bind to the negative charged N-terminal region of tau,
with a similar effect on tau assembly [32], since we did not
test a tau variant containing the N-terminal and the tubu-
Effect of 3-APS on tau-actin complexesFigure 5
Effect of 3-APS on tau-actin complexes. As indicated in Figure 1, tau expresing HEK cells show some lamellipodia regions 
that are stained by both, phalloidin (aggregated actin) and tau antibodies. The merged picture is also indicated. DAPI was used 
for nuclei staining (A). In the presence of 200 µM 3-APS, the phalloidin and Tau staining clearly decreases (B).Page 6 of 12
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APS to the N-terminal region of tau may influence the
binding of tau to membrane-actin aggregates [33].
The proposed mechanism to explain the assembly of tau
in the presence of 3-APS could not be very different to that
suggested for heparin-induced tau assembly. In both cases
a tau peptide comprising residues 317 to 335 is enough to
form aggregates [34]. In addition, 3-APS could act as a
sequestering molecule for tau, but it could not be essential
for cell viability. In this way it has been described that the
mice lacking tau could develop and live like their wild
type counterparts [35].
There is evidence for a role of sGAG in the formation of
amyloid and tau aggregates [36] and, as indicated in the
introduction, a possible toxic effect by promoting amy-
loid peptide aggregation was suggested for sGAG, but,
conversely, it has been described that sGAG like heparan
or chondroitin sulfate attenuate the neurotoxic effect of
amyloid peptide in primary neuronal cultures [37], and a
role for heparan sulfate as a modulator of Aβ formation,
through beta secretase, has been suggested [38]. It will be
of interest in further studies, to test for a possible effect of
3-APS on beta secretase activity.
Regarding tau protein, it has been reported that the chon-
droitin sulfate content inversely correlates with the
amount of hyperphosphorylated tau in cortical areas of
Alzheimer's disease patients [39]. Thus, a posible neuro-
protective role of sGAG in Alzheimer's disease could not
be excluded, and the neuroprotective role could be
extended to some related compounds like 3-APS, because
3-APS could be used for decreasing Aβ pathology and,
although it aggregates tau protein, it is not toxic for cul-
tured cells. Moreover, 3-APS promotes the decrease of tau-
actin complexes [28,29] that could be toxic for the cells
[24].
Conclusion
We suggest that drugs of potential interest for the treat-
ment of Alzheimer's disease should be tested not only on
one of the proteins involved in Alzheimer's disease
pathology, like amyloid peptide, but also on the compo-
nent of the other pathological hallmark of Alzheimer's
disease, tau protein. Our data, although support the lack
of effect of 3-APS in cell viability, indicate that 3-APS
could promote tau aggregation, probably reducing the
amount of available functional tau inside of a cell. This
relevant aspect should be taken into account for a possible
future use of Tramiprosate in human beings.
3-APS treatment is not affecting cell survivalFigure 7
3-APS treatment is not affecting cell survival. Non 
neuronal (HEK 293 Tau cells) were treated with 3-APS. Via-
ble and dead cells were stained with calcein AM and propid-
ium iodide as described in "methods" and photographed at a 
fluorescence microscope. Percentages of specific cell survival 
were determined as described in "methods".
Polymers found when 3-APS was added to tau protein and s me tau ragmentsFigur  6
Polymers found when 3-APS was added to tau pro-
tein and some tau fragments. A) Scheme of tau and its 
fragments used in this analysis. B) Polymer formation after 
incubation of tau protein, N-terminal tau region, 3R tau frag-
ment and 3RC tau fragment, with 3-APS. Inset shows the pol-
ymers found after incubation of tau peptide (residues 317–
335) with 3-APS. Bars indicate 0.2 µmPage 7 of 12
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The effect of 3-APS in neuronal cellsFigure 8
The effect of 3-APS in neuronal cells. A) Expression of tau protein was determined by western blot in non differentiated 
(0 days) and after starting differentiation for four days (4) or after eight days (8) with 2 mM dibutyril cyclic cAMP (cAMP) in SH-
SY5Y neuroblastoma cells. Actin was taken as a control of loading protein. B) Effect of 3-APS on undifferentiated SH-SY5Y 
cells. In the absence (control) of 3-APS, or in the presence of 100 µM 3-APS. Cells were stained with phalloidin to label actin 
cytoskeleton. C) Effect of 3-APS on differentiated SH-SY5Y cells. SH-SY5Y cells differentiated for 8 days were untreated (con-
trol) or treated with 100 µM 3-APS. The cells were stained with antibodies raised against tau protein and with phalloidin to 
label polymerized actin. D) In the presence of 3-APS there is an increase, in differentiated SH-SY5Y cells, in Th-S staining. 
Untreated, or cells treated with 100 µM 3-APS were stained with Th-S and visualized by an immunofluorescence microscopy 
(see methods). An increase in Th-S staining upon 3-APS treatment was found. E) Detergent insoluble tau aggregates were iso-
lated from neuroblastoma cells untreated or treated with 100 µM and 500 µM 3-APS. The amount of tau in detergent insoluble 
material was measured by testing its reaction with tau antibody 7.51. Actin was used as a loading control (see methods). F) Th-
S staining in hippocampal neurons treated with 3-APS. Primary cultures of hippocampal neurons were stained with Th-S in the 
absence (control) or the presence of 100µM 3-APS or 500 µM 3-APS. The quantitation of the fluorescent intensity is shown. 
(G) Effect of 3-APS in hippocampal neurons viability. Primary hippocampal cultures were incubated in the absence (control) or 
the presence of 100 µM, 500 µM and 1000 µM, for 24, 48 or 72 hours and the percentage of cell survival was determined.
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Materials
3-Amino-1-propanesulfonic acid (3-APS) (Ref. A4147),
Phenylmethylsulfonyl fluoride (PMSF), EDTA, EGTA, 2-
Mercaptoethanol, MES, HEPES, Trizma Base, NaF,
Na3VO4 and SDS were purchased from Sigma. Triton X-
100, Tween-20, NaCl and MgCl2 were obtained from
Merck. Acrylamide/bisacrylamide solution and Bradford
reagent was supplied by Bio-Rad. Protran Nitrocellulose
Transfer Membrane was from PerkinElmer. The chemilu-
miniscent detection kit (Western Light) was purchased
from Tropix. DAPI (Ref. 268298) was obtained from Cal-
biochem. Thioflavin S (Th-S) (Ref. T-1892) was purchased
from Sigma.
Antibodies
For immunoblot analysis, we used anti-β-tubulin (1/
2000; Sigma), anti-β-actin (1/2500; Sigma), and
7.51(anti-tau antibody; a gift from Dr. C. M. Wischik, UK)
antibodies followed by relevant secondary antibodies (1/
2000; DAKO).
For immunofluorescence, we used anti-β-tubulin (1/500;
Sigma), Tau-5 (1/500; Chemicon) and T14(1/500; Zymed
Laboratories). The secondary antibodies (Molecular
Probes) were used at 1/1000.
Actin staining was done by using phalloidin TRITC (1/
300; Sigma). 0,01% Thioflavin S in PBS 1× was used for
staining of treated or untreated cell cultures.
Reverse transcription of RNA and polymerase chain 
reaction (RT-PCR)
Total RNA from HEK 293 and HEK 293 tau expressing
cells were prepared using the reagent TRIzol (Invitrogen)
and following the supplier's protocol. Reverse transcrip-
tion was performed using the first cDNA synthesis kit
(Roche Applied Science) on 5 µg of RNA with oligo(dT)
primers. PCR was performed with the primers for tau R1
(5'-GGCGAATTCGGATCCATGCCAGACCTGAAGAATG-
3') and R2 (5'-GGCCTGC AGTTACTCGCGGAAGGT-
CAGCTTGTGGG-3'). The amplifications were performed
basically with the following protocol: 30 cycles of 94°C
for 45s, 55°C for 1 min, and 72°C for 1 min. The PCR
products were resolved on a 1% agarose gel and stained
with ethidium bromide. As a loading control, RT-PCR for
actin was performed for each sample. The used primers for
murine actin were H1 (5'-GCATGGAGTCCTG TGGCATC-
CACG-3') and H2 (5'-GGGTGTAACGCAACTAAGT-
CATAG-3'). Differences among groups were analysed by
Student's unpaired t-test to determine significant differ-
ences between means.
Cell culture
HEK 293 tau cells
HEK 293 tau expressing cells (expressing tau 3R isoform,
a kind gift from Dr. Miguel Medina) were grown in Dul-
becco's modified Eagle's medium (DMEM) supplemented
with 10% fetal bovine serum, 2 mM Glutamine, 1 mM
Piruvate, 100 U/ml penicillin, 100 U/mL streptomycin,
and 0.2 mg/ml Zeocin in a humified atmosphere of 5%
CO2/95% air at 37°C. Proliferating HEK 293 tau express-
ing cells were plated on glass cover slips coated with 1 mg/
ml poly-L-lysine, maintained in the same culture medium
during 24 hours and treated with 3-APS for 24,48 and 72
hours , at 100 µM, 500 µM 3-APS.
SH-SY5Y cells
Human neuroblastoma SH-SY5Y cells [40] were main-
tained in Dulbecco's modified Eagle's medium (DMEM)
supplemented with 10% fetal bovine serum, 2 mM
Glutamine, 100 U/ml penicillin, 100 U/mL streptomycin
in a humified atmosphere of 5% CO2/95% air at 37°C.
For differentiation, proliferating SH-SY5Y cells were
plated and then cultured in Neurobasal-B27 medium
(Gibco, Grand Island, NY) supplemented with 2 mM dib-
utyril cyclic AMP and 1 mM glutamine for 7 days. At this
time, about 90% of the cells has extended long neurites
and became postmitotic (showing no significant incorpo-
ration of tritiated thymidine into DNA).
After 7 days differentiated SH-SY5Y cells were treated dur-
ing 48 hours with 100 µM, 500 µM 3-APS.
Primary culture
Hippocampal neurons were cultured as described by
Banker and Cowan [41]. Pregnant wild type females were
sacrificed at gestional day 18, and the embryos were
removed in sterility. Dissociated hippocampal neurons
were plated on glass cover slips coated with 1 mg/ml poly-
L-lysine and then 20 µg/ml laminin. After incubating in
medium containing 10% horse serum (Gibco-BRL, Gaith-
ersburg, MD) for 24 hours, the medium was changed and
supplemented with N2 and B27 (Gibco-BRL). At this
point, neurons were treated with 3-APS for 24, 48 and 72
hours, at 100 µM, 500 µM 3-APS.
Cell Lysis and Western Blot Analysis
HEK 293 and HEK 293 tau expressing cells were washed
once with phosphate-buffered saline (PBS), placed on ice,
and then homogenized in a buffer containing: 20 mM
HEPES, pH 7.4; 100 mM sodium chloride (NaCl); 100
mM sodium fluoride (NaF); 1% Triton X-100; 1 mM
sodium orthovanadate (Na3VO4); 5 mM EDTA; and the
Complete protease inhibitor cocktail (Roche Diagnostics,
Barcelona, Spain). After determination of the protein con-
tent via Bradford assay, samples containing the same
amount of protein were mixed with electrophoresis bufferPage 9 of 12
(page number not for citation purposes)
Molecular Neurodegeneration 2007, 2:17 http://www.molecularneurodegeneration.com/content/2/1/17containing sodium dodecyl sulfate (SDS), boiled for 5
min, and separated by gel electrophoresis in the presence
of SDS on 10% acrylamide gels. The proteins were then
transferred to nitrocellulose membranes by following
standard procedures, and the membranes were blocked
with 10% nonfat dried milk in PBS, 0.2% Tween-20
(PBST). The blocked membranes were incubated over-
night with primary antibodies diluted in blocking solu-
tion at 4°C. The membranes were then rinsed three times
in PBST and incubated with the corresponding peroxi-
dase-conjugated secondary antibody for 1 hr at room tem-
perature. The immunoreactive proteins were visualized by
using an enhanced chemiluminescence detection system
(Amersham), and subsequent densitometric analysis was
performed with an imaging densitometer (GS-710 model;
Bio-Rad, Hercules, CA). Western blot analysis were also
done using an antibody raised aginst actin (Sigma) as
loading control. Protein extracts prepared from differeti-
ated SH-SY5Y cells were processed and analysed by West-
ern Blot using tau antibody 7.51 (1/100) as previously
indicated.
Immunoblot analysis of aggregated Tau
Treated HEK 293 tau expressing cells, or SH-SY5Y neurob-
lastoma cells, were homogenized in RIPA buffer (50 mM
Tris-HCl (pH 8.0), 150 mM NaCl, 5 mM EDTA, 1% Non-
idet P-40, 0.25% sodium deoxycholate, 1% SDS, 5 mM 4-
(2-aminoethyl) benzene-sulfonyl fluoride hydrochloride,
1 µg/ml proteases inhibitors (Complete protease inhibi-
tor cocktail (Roche Diagnostics, Barcelona, Spain)), 1 mM
NaF, 1 mM Na3VO4, and 1 mM β-glycerophosphate)
without thawing by using a polytron homogenizer (Kine-
matica, Kriens, Switzerland) at its highest speed for 30 s.
Before centrifugation to fractionate the detergent soluble
from detergent insoluble material, an aliquot from each
sample was taken to determine if each sample contains, or
not, a similar amount of actin (loading control). To do
that we have used an antibody raised against actin. Tau
protein aggregates from homogenates were isolated by
centrifugation (4°C) for 20 min at 20000–30000 g (table-
top centrifuge at 15000 rpm). One fourth of the superna-
tant volume, after centrifugation, was taken to character-
ize the protein present in that fraction. The whole
aggregated protein present in the insoluble fraction was
then diluted in O+ buffer (62.5 mM Tris-HCl pH 7.0, 10%
(w/v) glycerol, 5% (v/v) β-mercaptoethanol, 2.3 % (w/v)
SDS, 1 mM EDTA, 1 mM EGTA, 1 mM NaF, 1 mM Na3VO4
1 mM PMSF (phenylmethyl-sulfonyl fluoride), 1 µg/ml
proteases inhibitors (Complete protease inhibitor cocktail
(Roche Diagnostics, Barcelona, Spain)), boiled for 5 min,
and separated by gel electrophoresis in the presence of
SDS on 10% acrylamide gels. Then, the protein content
was analized by western blot as previously described.
Immunofluorescence analysis
After treatments, HEK 293 and HEK 293 tau expressing
cells were fixed with either cooled methanol (-20°C)
(tubulin immunofluorescence) or 4% paraformaldehyde
(actin and tau immunofluorescence) for 20 min at 4°C or
37°C, respectively, and then washed with buffer A (0.1 M
MES; 2 mM EGTA; 0.5 mM MgCl2) or with phosphate
buffered saline (PBS), respectively. Fixed cells were incu-
bated with 1 M glycine 30 min then permeabilized with
0.2% Triton X-100 in PBS or buffer A for 5 min at room
temperature. The cover slips were blocked with 1% BSA/
PBS or Buffer A for 1 h at room temperature and incubated
in primary antibodies in 1% BSA, in PBS, or in buffer A,
for 1 h at room temperature. After washing three times
with PBS or with buffer A, the secondary antibodies were
incubated for 1 h, at room temperature. DAPI (1 µg/ml)
staining was performed 10 minutes before finishing sec-
ondary antibody incubation. Finally, the covers lips were
washed three times with PBS or with buffer A and once
with H2O, and mounted with FluorSave Reagent (Calbio-
chem).
Fluorescence microscopy was used to measure fluores-
cence intensity. After staining with 0.01 % Th-S and T14
antibody cell were observed on a Zeiss Axiovert200 fluo-
rescent microscope. T14 antibody and thioflavin-S fluo-
rescence images were captured through a 100× objetive on
a high resolution CCD camera (SPOT RT Slider, Diagnos-
tic). The images were saved for later analysis and quanti-
tation. Camera exposure and light settings were keot
constant during each experiment. The fluorescence inten-
sity measurements were carried out using the image anal-
ysis software Metamorph 6.1 r6 (Universal Imaging).
A similar protocol was followed for SH-SY5Y neuroblast-
oma cells and primary cultures of hippocampal neurons.
Binding of tau to microtubules
For in vitro assembly of tau protein with microtubules,
purified tubulin was assembled in the presence of taxol
[42] and mixed with tubulin, after incubation of the mix-
ture, the polymerized protein was isolated by centrifuga-
tion in Airfuge (Beckman) at room temperature, for 15
min at 100000 g. The protein present in supernatant and
pellet was analyzed by gel electrophoresis followed by
western blot using anti-tau and anti-tubulin antibodies.
Determination of Cell Viability
Cell viability was assessed by calcein-propidium iodide
uptake [43]. Calcein/acetoxymethyl ester is taken up and
cleaved by esterases present in living cells, yielding yel-
lowish-green fluorescence. In contrast, propidium iodide
is taken up only by dead cells, which then exhibit orange-
red fluorescence. Briefly, cells were incubated for 30 min
with 8 µM propidium iodide (Sigma) and 1 µM calcein/Page 10 of 12
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then rinsed once with Hanks balanced salt solution con-
taining 2 mM CaCl2, and the cells were visualized by flu-
orescence microscopy with a Zeiss Axiovert 135
microscope. Three randomly selected fields were analyzed
per well (100–200 cells/field) in at least three independ-
ent experiments. Cell viability was expressed as the per-
centage of calcein-positive cells with respect to the total
number of cells.
Protein and peptide preparation
Recombinant human tau (whole molecule), N-terminal
tau (residues 1–251), peptide 3RC (containing three
tubulin binding motifs and the carboxyl-terminal region),
peptide 3R (containing three tubulin binding motifs),
have been synthesized and purified as previously reported
[4]. Tau peptide containing residues 317–335 was
obtained as previously indicated (meter referencia 33).
Assembly of Tau Peptides into Filaments
Filaments were grown by vapor diffusion in hanging
drops in the standard way used for protein crystallization
as previously indicated [44]. In a typical experiment, 0.5–
2 µg of peptide was resuspended in 10–15 µL of buffer A
(0.1 M MES (pH 6.4), 0.5 mM MgCl2, and 2 mM EGTA)
containing 50 mM NaCl and 3-APS at concentrations
ranging from 1 to 4 mM. In other assays, a similar amount
of tau (0.5–2 µg) but in the presence of 0.5 mg/mL
heparin was resuspended in buffer A [4]. The reservoir in
this case contained 0.2 M NaCl in buffer A. Filaments were
obtained after incubation for 4 days at 4°C. The samples
we revisualized by electron microscopy as described [4].
Electron micrographs were obtained at a magnification of
80000 on Kodak SO-163 film. Micrographs were digitized
using an Eikonix IEEE-488 camera with a pixel size equiv-
alent to 7 Å in the specimen plane. Processing and meas-
urements were performed using the Digital micrograph
2.1 software from Gatan. Several standards were used for
the control of the measurements. Alternatively, tau poly-
mers were stained with Th-S and visualized by immun-
ofluorescence [27].
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